股票代码：000423 股票简称：东阿阿胶 五、关于管理层的稳定性与战略执行 未来一定时期内，管理团队将保持总体稳定，上下同欲，坚定执行 "1238"战略，推动公司经营稳健发展。 东阿阿胶股份有限公司 2024 年年度股东大会记录表 编号：2025-04 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 □业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | √现场参观□其他 | | 参与单位名称 | 参加公司 2024 年年度股东大会的股东及委托代理人 | | 及人员姓名 | | | 时间 | 2025 年 5 月 20 日 | | 地点 | 山东省东阿县阿胶街 78 号 公司会议室 | | | 董事长程杰 | | 上市公司 | 独立董事 文光伟 | | 接待人员姓名 | 董事、副总裁、董事会秘书、财务总监丁红岩 | | | 证券事务代表、董事会办公室总经理 付延 一、关于股份回购的规划 | | | 作为市值管理工具之一，股份回购在提振资本市场信心、稳定股价 等方面具有一定作用。基于当前经营实际，公司将保持对股份回购等事 | | | 项的 ...

康弘药业：去年舒肝解郁胶囊实现超过抗抑郁整体市场的增长，KH109有望扩大适用人群 5月15日，康弘药业举办2024年度网上业绩说明会。会上管理层谈到，2024年度，舒肝解郁胶囊同比有两位数以上的 增长，超过抗抑郁整体市场的增长。舒肝解郁胶囊作为中成药，有起效相对更快、不良反应更少、长期安全性高等优 势，减轻了患者的用药心理负担，有助于患者积极治疗。公司看好舒肝解郁胶囊销售的后期持续发展。焦虑症的临床 研究目前稳步推进，公司已于2025年4月完成了Ⅲ期临床试验入组。有望进一步扩大适用人群。 东阿阿胶：高度重视驴皮持续性保供，目前驴皮价格基本稳定 5月15日，东阿阿胶参与2025年山东辖区上市公司投资者网上集体接待日。期间管理层介绍，2024年公司阿胶块营收 占比约45%左右，复方阿胶浆占比约近35%。公司高度重视驴皮持续性保供等相关工作，持续专注于国内驴皮和国际 驴皮供应两大市场，兼顾驴皮获取与资源涵养。驴皮价格与毛驴养殖成本、规模、进口情况等多项因素有关，目前驴 皮价格基本稳定。 恒瑞医药拟全球发售2.25亿股H股：发行价最高44.05港元，7家基石投资者认购逾41亿港元 5月15日，恒瑞医药正式启动H股全 ...

股票代码：000423 股票简称：东阿阿胶 东阿阿胶股份有限公司投资者关系活动记录表 编号：2025-03 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 □业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 √其他 | | 参与单位名称 参加 及人员姓名 | 2025 年山东辖区上市公司投资者网上集体接待日活动的投资者 | | 时间 | 2025 年 5 月 15 日（周四）15:00—16:30 | | 地点 | 全景网"投资者关系互动平台"（http://rs.p5w.net） | | | 董事长 程杰 | | 上市公司 | 董事、总裁 孙金妮 | | 接待人员姓名 | 董事、副总裁、董事会秘书、财务总监 丁红岩 | | | 证券事务代表、董事会办公室总经理 付延 一、关于公司未来经营规划 | | | 东阿阿胶将坚定以"1238"战略为指引，深化推进胶类产业链 "三产融合"协同发展，继续做强做优做大阿胶主业，精准拓深基石业 | | | 务，统筹拓展潜力产品，着力培育外延品种。持续深化"一中心 三高 | | 地+N | ...

Core Insights - The company is focusing on its product segmentation, with approximately 45% of revenue coming from traditional Ejiao blocks and nearly 35% from compound Ejiao syrup in 2024 [1] - The brand Royal Weichang 1619 aims to strengthen its position in the men's health sector, emphasizing a vision of upgrading the Northeast industry and focusing on key strategies for brand and product development in 2025 [1] - The company is committed to ensuring a stable supply of donkey hides, which are crucial for its production, while maintaining a balance between domestic and international sourcing [1] Financial Performance - In the first quarter, the company reported good terminal sales performance and reassessed its strategic credit support based on the scale of cooperation with strategic clients [2] - The accounts receivable increased compared to the beginning of the year, but the management indicated that the sales collection and accounts receivable levels remain reasonable and controllable [2] - The company plans to maintain its established credit management strategy to ensure a healthy level of accounts receivable [2] Strategic Initiatives - The company is enhancing its brand strategy for the "Peach Blossom Princess" line, focusing on revitalizing the brand and establishing its position in the beauty and health market [1] - The management is increasing the procurement of strategic materials such as donkey hides and traditional Chinese medicinal herbs, which has led to higher capital expenditures [2] - The company expects to see an increase in cash flow from operations as bank acceptance bills mature and collections improve [2]

Group 1: Company Performance and Financials - In 2024, the company achieved operating revenue of 2.371 billion yuan and a net profit attributable to shareholders of 216 million yuan, with cash flow from operating activities increasing by 83.14% to 199 million yuan [2] - The company aims to maintain high-quality development despite challenges from rising raw material prices, focusing on product-centric strategies and diversifying its product portfolio [2][3] Group 2: Innovation and R&D - The company is actively developing its stem cell research, with ongoing clinical trials for treatments related to ischemic stroke and autoimmune diseases, having enrolled 31 and 8 participants respectively [3] - A GMP-compliant stem cell R&D production base has been established, meeting both Chinese and U.S. drug application standards, and the company has received CNAS certification [3] Group 3: Shareholder Returns - The company announced a cash dividend of 3 yuan per 10 shares for the 2024 fiscal year, with the dividend record date on May 7 and payment on May 8 [4] - Cumulatively, the company has distributed over 4 billion yuan in dividends since its listing [5] Group 4: Corporate Governance - In January, the company underwent a change in control, with the Heilongjiang Provincial State-owned Assets Supervision and Administration Commission becoming the new actual controller, which is expected to enhance operational efficiency and market competitiveness [6]

Core Insights - The company achieved a revenue of 5.921 billion yuan in 2024, representing a year-on-year growth of 25.57% and a net profit attributable to shareholders of 1.557 billion yuan, up 35.29% [1] - The company is driven by a dual engine of pharmaceutical and health consumer products, with significant growth in its core product lines [2] - The company has introduced an employee stock incentive plan to enhance talent attraction and promote long-term high-quality development [2] Financial Performance - In 2024, the company reported a net operating cash flow of 2.171 billion yuan, reflecting an 11.13% increase year-on-year [1] - The basic earnings per share (EPS) for 2024 was 2.42 yuan, marking a 35.20% increase compared to the previous year [1] - The company maintained a strong financial structure with a debt-to-asset ratio of 21.05% and cash reserves of 5.015 billion yuan at the end of the year [2] Business Segments - Revenue from the company's Ejiao and related products reached 5.544 billion yuan, a year-on-year increase of 27.04%, with a gross margin of 73.61% [2] - Other pharmaceuticals and health products generated revenue of 236 million yuan, up 26.19% year-on-year [2] - The company experienced a decline in revenue from donkey breeding and sales, which amounted to 69 million yuan, down 28.92% [2] Growth Initiatives - The company launched a stock incentive plan, proposing to grant up to 124.72 million restricted shares, representing 0.19% of the total share capital, to 179 key personnel [2] - The performance targets for the incentive plan include a compound annual growth rate of net profit attributable to shareholders of no less than 15% from 2025 to 2027 [2] - The company has a history of high dividends, with a mid-year dividend of 737 million yuan in 2024, representing 99.77% of the net profit attributable to shareholders for the first half of the year [2] Investment Outlook - The company is expected to achieve EPS of 2.87 yuan, 3.40 yuan, and 4.02 yuan for the years 2025 to 2027, with corresponding dynamic P/E ratios of 21.91, 18.53, and 15.66 [3] - As a leader in the Ejiao industry, the company possesses strong brand barriers and is anticipated to achieve steady growth in performance [3]

股票代码：000423 股票简称：东阿阿胶 东阿阿胶股份有限公司投资者关系活动记录表 公司实施阶段性授信清零的管理策略，年初结合战略客户合作规 模等维度，系统性评估核定战略授信的支持力度。2025 年一季度，额 度内使用授信发货，形成应收账款较年初有所增加。同时，部分跨期银 行承兑汇票未到期，以及加大驴皮原料及中药材等战略物资储备，采购 资金支出增加，从而影响经营活动现金水平。 七、关于复方阿胶浆医保占比 目前，复方阿胶浆医保支付占一定体量，其中统筹支付比例较小。 未来，复方阿胶浆将持续深化大品种战略落地落实，保持稳健可持 续增长态势。 编号：2025-02 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者 | □媒体采访 √业绩说明会 | | 关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称 | 瑞银证券、开源证券、华创证券等券商分析师及广大投资者朋友 | | 及人员姓名 | | | 时间 | 2025 年 4 月 29 日 | | 地点 | 公司会议室 | | 上市公司 | 董事、总裁 孙金妮 | | 接待人员姓名 | 董事、 ...

证 券 研 究 报 告 东阿阿胶（000423）2025 年一季报点评 推荐（维持） 勿因短期现金流而低估经营韧性 目标价：72.5 元 事项： 公司公告 1Q25 实现收入 17.2 亿元（+18.2% yoy）、归母净利 4.3 亿元（+20.2% yoy）、扣非净利 4.2 亿元（+26.7% yoy），并召开一季度业绩说明会，对市场较 为关注的现金流及应收账款等财务指标变化进行解读。 评论： [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 5,921 | 6,919 | 8,022 | 9,191 | | 同比增速(%) | 25.6% | 16.9% | 15.9% | 14.6% | | 归母净利润(百万) | 1,557 | 1,869 | 2,205 | 2,602 | | 同比增速(%) | 35.3% | 20.0% | 18.0% | 18.0% | | 每股盈利(元) | 2.42 | 2.90 | 3.42 | ...

Core Insights - Dong-E E-Jiao achieved strong performance in Q1 2025, with revenue of 1.719 billion yuan, a year-on-year increase of 18.24%, and a net profit of 425 million yuan, up 20.25% [1][2] - The company continues to implement a dual-driven strategy of "pharmaceuticals + health consumer products," contributing to its robust growth [2][3] - The gross profit margin improved significantly from 47.57% in 2019 to 73.63% in Q1 2025, driven by digital supply chain upgrades and a focus on high-margin products [1][2] Financial Performance - In Q1 2025, the company reported a net profit of 425 million yuan, with a non-recurring net profit of 416 million yuan, reflecting a growth of 26.69% [2] - Compared to Q4 2024, revenue increased by 7.98% and net profit grew by 4.93% [2] - The sales expense ratio decreased by 2.6 percentage points to 36.26%, while the management expense ratio stood at 5.04%, indicating effective cost control [2] Product Development - Dong-E E-Jiao is expanding into the men's health supplement market, introducing products like brain and kidney tonics, and has plans for further innovation [3] - The company continues to lead the OTC market with its core product, Dong-E E-Jiao blocks, and has seen strong sales in innovative products like instant dissolvable E-Jiao powder and ready-to-eat freeze-dried E-Jiao series [2][3] Strategic Moves - The company is divesting its 15% stake in China National Pharmaceutical Group Jinan, indicating a strategic focus on its core business of E-Jiao and related products [3] - Dong-E E-Jiao aims to solidify its position as the leading brand in health supplements by concentrating resources on its main business [3] Research and Development - Over the past five years, Dong-E E-Jiao has invested 787 million yuan in R&D, with annual expenditures showing a consistent commitment to innovation [4][5] - The company has established a collaborative innovation platform, focusing on developing high-quality health products and traditional Chinese medicine [5]

证券研究报告·公司点评报告·中药Ⅱ 东阿阿胶（000423） 2025 年一季报点评：业绩符合预期，高分红， 稳增长 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 4,715 | 5,921 | 6,878 | 7,859 | 8,918 | | 同比（%） | 16.66 | 25.57 | 16.16 | 14.26 | 13.47 | | 归母净利润（百万元） | 1,151 | 1,557 | 1,864 | 2,215 | 2,565 | | 同比（%） | 47.55 | 35.29 | 19.73 | 18.80 | 15.83 | | EPS-最新摊薄（元/股） | 1.79 | 2.42 | 2.89 | 3.44 | 3.98 | | P/E（现价&最新摊薄） | 30.84 | 22.79 | 19.04 | 16.02 | 13.83 | [Table_Tag] [Table_Summa ...